Bloomberg News

Teva Rises Most in 2 Months in Tel Aviv After Naming New CEO

January 03, 2012

(Updates with closing share price in second paragraph)

Jan. 2 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. rose the most in two months after the world’s largest generic drugmaker said Jeremy Levin, a former executive at Bristol-Myers Squibb, will replace Chief Executive Officer Shlomo Yanai.

The shares gained 3.3 percent, the most since Nov. 3, to 160.60 shekels at the 4:30 p.m. close in Tel Aviv.

--Editors: Susan Lerner, Claudia Maedler

To contact the reporter on this story: Gwen Ackerman in Jerusalem at

To contact the editor responsible for this story: Claudia Maedler at

The Good Business Issue
blog comments powered by Disqus